Skip to main content

When to Stop Medications in Advanced Dementia


by: Claire Larson

Throughout medical training, we devote extensive time learning when to start medications. We memorize the pharmacology, indications for use, side effects, and sentinel trials showing their efficacy. Yet, not until my fellowship training in Geriatrics, did I learn another key part of medication prescribing: when to stop.

We’ve all seen it: patients with lists of 10, 20 or more medications, to which we are always adding and never subtracting. Most were added with good intentions and defined indications, but over time, like the medications themselves, the indications expire.

The case of one of my home visit patients stands out: a 65 year-old man with very advanced early onset Alzheimer’s disease. Bedbound, nonverbal, and aspirating, when I became his primary care provider, he was still taking donepezil and memantine, which he had taken for the last 10 years. When I discussed his care with his neurologists, they were reluctant for these medications to be stopped for fear of him worsening, despite recognizing that there was no evidence to support continued benefit.

I recently led a journal club where we reviewed, “Use of Medications of Questionable Benefit in Advanced Dementia.”1 This cross-sectional study examined medication use by nursing home residents with advanced dementia. Medications of questionable benefit were defined as “never appropriate” medications as determined by the consensus of a group of Geriatricians.2

Over half of nursing home residents with advanced dementia (53.9%) received at least one medication of questionable benefit. The most commonly prescribed were cholinesterase inhibitors (36.4%) and memantine hydrochloride (25.2%). Continuing these medications does not increase survival or alter the course of advanced disease, can cause side effects, and contributes to increased health care costs.3

So why are so many patients with advanced dementia still taking medications of questionable benefit?

While stopping a medication may seem straightforward, as clinicians we know that stopping a medication is frequently more difficult than starting one. We often lack the knowledge and evidence to help us know when to discontinue medications.

Next, stopping medications involves discussing the balance of risks and benefits with patients and their families, and probably hardest, explaining that the disease has advanced beyond the point where the medication is helpful. For the families of my patients with dementia, stopping donepezil or memantine is most difficult, for this is often closely tied to their hope that the medication will cease or significantly slow the progressive course of the disease.

As clinicians we also may be uncomfortable taking away medications, as we are trained to always “do” something. But stopping these medications does not mean we stop caring for the patient, we simply shift our focus.

For my patient, a focus on careful hand-feeding and skin care, quality time spent with his family, and continued enjoyment of music and time outdoors was more important and helpful than any medication. Learning and studying when to stop medications, can help us start taking better care of our patients.


References

  1. Tjia J, Briesacher BA, Peterson D, Liu Q, Andrade SE, Mitchell SL. Use of medications of questionable benefit in advanced dementia. JAMA Intern Med. 2014;174(11):1763-1771. 
  2. Holmes HM, Sachs GA, Shega JW, Hougham GW, Cox Hayley D, Dale W. Integrating palliative medicine into the care of persons with advanced dementia: identifying appropriate medication use. J Am Geriatr Soc. 2008;56(7):1306-1311. 
  3. Buckley, JS and Salpeter, SR. A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence. Drugs Aging. 2015 May 5. [Epub ahead of print]

Comments

newton juma said…
Quite an an informative article, thanks. Newton@ Kenyatta University School of Medicine
Mike Steinman said…
Bravo Claire on a thoughtful piece. Treating the patient, not the disease, is where the geriatric approach shines. As you note, the way we manage medications should follow this same principle.
JP said…
Since I became a consultant and was then fully responsible for my acts, decided that this was the main role of a Geriatrician, few specialities actually focus on when to stop and what not to do rather than continue on prescribing and adding non sense ... Once I discharge an end stage, bed bound patient with major neurocognitive disorder probable due to Alzheimer's disease with the prescription of Ice cream as required. This was the only thing she would take and refuse everything else.

Popular posts from this blog

Are Palliative Care Providers Better Prognosticators? A Podcast with Bob Gramling

Estimating prognosis is hard and clinicians get very little training on how to do it.  Maybe that is one of the reasons that clinicians are more likely to be optimistic and tend to overestimate patient survival by a factor of between 3 and 5.  The question is, aren't we better as palliative care clinicians than others in estimating prognosis?  This is part of our training and we do it daily.   We got to be better, right? 

Well, on todays podcast we have Bob Gramling from the Holly and Bob Miller Chair of Palliative Medicine at the University of Vermont to talk about his paper in Journal of Pain and Symptom Management (JPSM) titled “Palliative Care Clinician Overestimation of Survival in Advanced Cancer: Disparities and Association with End of Life Care”.

Big findings from this JPSM paper include that we, like all other clinicians, are an optimistic bunch and that it actually does impact outcomes.   In particular, the people whose survival was overestimated by a palliative care c…

Delirium: A podcast with Sharon Inouye

In this week's GeriPal podcast we discuss delirium, with a focus on prevention. We are joined by internationally acclaimed delirium researcher Sharon Inouye, MD, MPH. Dr Inouye is Professor of Medicine at Harvard Medical School and Director of the Aging Brain Center in the Institute for Aging Research at Hebrew SeniorLife.

Dr. Inouye's research focuses on delirium and functional decline in hospitalized older patients, resulting in more than 200 peer-reviewed original articles to date. She has developed and validated a widely used tool to identify delirium called the Confusion Assessment Method (CAM), and she founded the Hospital Elder Life Program (HELP) to prevent delirium in hospitalized patients.

We are also joined by guest host Lindsey Haddock, MD, a geriatrics fellow at UCSF who asks a great question about how to implement a HELP program, or aspects of the program, in a hospital with limited resources.  


You can also find us on Youtube!


Listen to GeriPal Podcasts on:
iTunes…

The Dangers of Fleet Enemas

The dangers of oral sodium phosphate preparations are fairly well known in the medical community. In 2006 the FDA issued it’s first warning that patients taking oral sodium phosphate preparations are at risk for potential for acute kidney injury. Two years later, over-the-counter preparations of these drugs were voluntarily withdrawn by the manufacturers.  Those agents still available by prescription were given black box warnings mainly due to acute phosphate nephropathy that can result in renal failure, especially in older adults. Despite all this talk of oral preparations, little was mentioned about a sodium phosphate preparation that is still available over-the-counter – the Fleet enema.

Why Oral Sodium Phosphate Preparations Are Dangerous 

Before we go into the risks of Fleet enemas, lets spend just a couple sentences on why oral sodium phosphate preparations carry significant risks. First, oral sodium phosphate preparations can cause significant fluid shifts within the colon …